// STATE LEGISLATION TRACKER

Hawaii HB 1625: RELATING TO CANNABIS.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Hawaii
Bill: HB 1625
Session: 2026
Filed: 2026-01-20
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

HB1625 is a cannabis and hemp regulation bill, not a peptide, pharmacy compounding, telehealth, or clinician-scope bill. Based on the title, subjects, and available status information, it does not appear to change access to compounded peptides, off-label prescribing, FDA 503A/503B compounding, NP or naturopathic scope, or prescription monitoring for peptides.

Key Points

No direct change to compounded peptide access is apparent.
No apparent change to off-label prescribing for peptides.
No apparent telehealth rule change for peptide care.
No apparent change to NP or naturopathic peptide scope.
Cannabis rules may change, but peptide rules are not the target.

What to Watch For

Note Track only if later amendments add pharmacy, prescribing, controlled-substance, or telehealth language.

Note Cannabis-related controlled-substance changes do not automatically affect peptide prescribing.

Note Any agency rulemaking should be checked for spillover into broader health or pharmacy regulation.

Where the Bill Stands

The bill was prefiled for the 2026 session and later referred to committees, but available tracking shows it did not pass.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws